Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company that develops therapeutics designed to modify the course of cardiopulmonary diseases. The company focuses primarily on treatments for pulmonary arterial hypertension, an orphan disease marked by elevated pulmonary vascular resistance and vascular remodeling. Its primary product candidate is IKT-001, an oral prodrug of imatinib designed to minimize gastrointestinal adverse effects by exhibiting lower inhibitory activity at target tyrosine kinases such as c-Kit. As a clinical-stage entity, the company does not currently sell commercial products to end customers, but its pipeline targets patients suffering from pulmonary arterial hypertension.

The company's clinical operations include a two-part adaptive Phase 3 study known as IMPROVE-PAH, which spans approximately 180 planned clinical trial sites internationally. The company maintains principal executive offices located in Wilmington, Delaware. In addition, it operates corporate subsidiaries that include IKT Securities Corporation in Massachusetts and CorHepta Pharmaceuticals, Inc. in Delaware.

Summary of the business section of Inhibikase Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of the date of this Annual Report, we had thirty-five full time employees and no part-time employees.”